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A national observation study 
of cancer incidence and mortality 
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over time
Hulda Hrund Bjornsdottir1,2, Araz Rawshani2,3, Aidin Rawshani2,3, Stefan Franzén2,4, 
Ann‑Marie Svensson2,3, Naveed Sattar 5* & Soffia Gudbjörnsdottir2,3
We examined changing patterns in cancer incidence and deaths in diabetes compared to the 
background population. A total of 457,473 patients with type 2 diabetes, included between 1998 and 
2014, were matched on age, sex, and county to five controls from the population. Incidence, trends in 
incidence and post‑cancer mortality for cancer were estimated with Cox regression and standardised 
incidence rates. Causes of death were estimated using logistic regression. Relative importance of risk 
factors was estimated using Heller’s relative importance model. Type 2 diabetes had a higher risk for 
all cancer, HR 1.10 (95% CI 1.09–1.12), with highest HRs for liver (3.31), pancreas (2.19) and uterine 
cancer (1.78). There were lesser increases in risk for breast (1.05) and colorectal cancers (1.20). Type 
2 diabetes patients experienced a higher HR 1.23 (1.21–1.25) of overall post‑cancer mortality and 
mortality from prostate, breast, and colorectal cancers. By the year 2030 cancer could become the 
most common cause of death in type 2 diabetes. Persons with type 2 diabetes are at greater risk of 
developing cancer and lower chance of surviving it. Notably, hazards for specific cancers (e.g. liver, 
pancreas) in type 2 patients cannot be explained by obesity alone.
Coronary heart disease (CHD) rates are half of what they were in the  1980s1 and data shows that cancer has now 
become the leading cause of death in many European  countries1–3. A growing body of evidence demonstrates 
that type 2 diabetes confers an increased risk of total cancer and site-specific cancers and furthermore, that it 
may affect  prognosis4–13. Type 2 diabetes and cancer share certain risk factors that might contribute to these 
associations (e.g. obesity, smoking, and  diet6,13,14). That noted, existing evidence suffers to differing extents 
from biases such as residual confounding, investigation bias, uncertainty due to self-reported information, and 
reverse  causality5,6. There is an abundance of studies evaluating the association of type 2 diabetes with cancer 
 mortality7,10,15–20, but fewer studies on risk for incident cancers in type 2 diabetes in relation to matched  controls6. 
Also, few studies have looked at both incidence and mortality in nationally representative populations. There 
is a need for a study with a large sample size examining both incidence and mortality from cancer for persons 
with type 2 diabetes. With cancer now being a more common cause of death and both incidence and prevalence 
of diabetes increasing  worldwide3,21,22, the association between these two outcomes might make the burden of 
these diseases a substantial global health challenge.
We evaluated (1) time trends in causes of death, (2) incidence of all cancer and site-specific cancers, (3) 
time-trends in cancer incidence and (4) post-cancer mortality among patients with type 2 diabetes compared 
to matched controls from the general population. We also compared our incident cancer risks with previously 
published work on BMI and  cancer23 in order to evaluate if type 2 diabetes may have an effect on risk for some 
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cancers independent of obesity. Finally, we evaluated the ability of routine risk factors to predict cancer incidence 
for type 2 diabetes, using one of the world’s largest diabetes databases.
Methods
Study design and support. The study was supported by the European Foundation for the Study of Dia-
betes, the Swedish Association of Local Authorities and Regions and the Swedish Heart and Lung Foundation 
and all methods were performed in accordance with the relevant guidelines and regulations; no support was 
provided by industries. The ethics review board at the University of Gothenburg approved the study.
Data sources. The Swedish National Diabetes Register (NDR), initiated in 1996, has been described 
 previously24,25. The register contains information on risk factors, treatment and complications of diabetes. Each 
patient provides informed consent for inclusion in the database. In 2017, all specialist clinics participated and 
95% of primary health care centers, and the register included approximately 90% of the diabetes population. 
For this study, persons with at least one listing in the NDR between 1998 and 2012 were included. Type 2 dia-
betes was defined by the epidemiologic definition: “Patients of all ages receiving only dietary treatment, or oral 
glucose-lowering agents only, or persons diagnosed after the age of 40 years receiving insulin therapy or insulin 
and oral glucose-lowering agents”. This definition has been validated against the clinician’s assessment of diabe-
tes type, which concur in 96% of cases with no temporal differences. In particular, none had gestational diabetes, 
pre-diabetes or, as far as we can determine type 1 diabetes. For each individual with type 2 diabetes, five controls 
were randomly selected from the general population. The control group was retrieved from the total popula-
tion register and was matched according to age, sex, and county. The controls are persons who during the study 
period do not develop T2DM and they enter into the cohort at the date when the corresponding T2DM person 
does. The cohort included 457,473 persons with type 2 diabetes and 2,2877,365 matched controls. The follow-up 
for persons with T2DM starts at the date of cohort entry.
The Total Population Register contains data on life events including birth, death, change of name, marital sta-
tus and migration. Almost 100% of births and deaths, 95% of immigrations and 91% of emigrations are reported 
to the register within 30 days26. From this register we obtained our matched controls. Data on cancer outcomes 
and all-cause death were retrieved from the Swedish Cancer Registry and the Swedish Cause of Death Registry. 
Information on comorbidities was retrieved from Swedish Patient Register and socioeconomic variables were 
retrieved from the Longitudinal Integration Database for Health Insurance and Labour Market Studies (LISA 
register). The Swedish Cancer Register registers cancer diagnoses in Sweden since 1958. Every clinician, patholo-
gist and cytologist are required to notify the register of every person who receives a diagnosis of a new primary 
malignancy. The register includes all primary malignancies and certain benign neoplasms and precancerous 
 lesions27. The Swedish Cause of Death register contains data for cause of death from the year 1952. The Cause of 
Death register includes everyone who died during one calendar year that was registered in Sweden at the time 
of death, regardless of whether they died in Sweden or outside the  country28. The LISA register is made from 
annual registers since 1990 and includes all persons 16 years and older who are registered in Sweden at December 
31st each year. The LISA register incorporates existing data from registers on labor market, education and social 
districts using background information from population  registers29.
Linkage of registries is virtually complete due to the use of unique personal identification numbers in Sweden, 
which are assigned to all habitants at birth or at the time of immigration.
Outcomes. All individuals were followed for a site-specific cancer occurrence, death, or end of follow-up, 
whichever came first. Follow-up was until 2013 for cancer occurrences and 2014 for mortality. Date and type 
of cancer diagnosis was retrieved from The Swedish Cancer registry, using ICD-7 codes. The specific codes are 
listed in Supplementary Table 1 in the online-only supplementary material. Causes of death were retrieved from 
the Cause of Death Register, using ICD-10 codes. Cause of death was defined as the principal cause in the death 
certificates; causes were categorised according to their ICD categories, with cardiovascular death being ICD 
codes starting with I, and cancer being ICD codes starting with C and D. Yearly incidence rates were standard-
ised by age and sex.
Statistical analysis. Cause of death was classified as cancer related, cardiovascular or other and modelled 
as a function of calendar year using multinomial regression models with year as a continuous independent vari-
able. The parameter estimates from the multinomial models were used for a rough prediction of when cancer 
and cardiovascular causes will be equally common.
We studied incidence of cancer and therefore patients with a pre-existing cancer diagnosis (in the Swed-
ish Cancer Registry) for a certain site-specific cancer were excluded from that specific cancer in the incidence 
analysis. Incidence rates, expressed as the number of events per 10,000 person-years, were calculated for each 
outcome. To compare the incidence rates for type 2 diabetes persons versus controls, we constructed a Cox 
regression model for all cancer incidence and for each site-specific cancer incidence. In this model, participants 
were followed from the index date until an event (date of cancer diagnosis), or appropriate censoring, using age 
as the time scale. Models were adjusted for sex, education, income, and marital status. Even if the persons with 
T2DM and the controls are matched on age, sex and county we had both variables in the model to avoid the omit-
ted variable bias that is a consequence of omitting important risk predictors from a Cox regression model. We 
repeated such analyses using patients with type 2 diabetes with less than 1 year diagnosis to relevant controls. We 
did this to minimise people with longer duration who may have higher cumulative cancer risk; useful therefore 
to also examine risks in recently (i.e. newly) diagnosed patients. To gain reasonable numbers, we chose to look 
at cancer risks in patients with less than 1 year of diabetes duration. The analysis was repeated as three separate 
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landmark analyses where the first one, two and three years were excluded to investigate the possible effect of 
detection bias or reverse causality that might be present shortly after the onset of T2DM.
To further explore how the incidence rate develops as a function of diabetes duration in newly diagnosed 
T2DM we estimated the yearly incidence rate, with exact Poisson 95% confidence interval for each year follow-
ing disease onset.
We also investigated the secular time trends in incidence for site specific cancers for type 2 diabetes versus 
controls by computing a Cox regression model with biannually time-updated calendar time as a continuous vari-
able. The model also includes an interaction term between calendar time and diabetes status (type 2 diabetes or 
control) allowing separate effects of calendar time to be estimated for type 2 diabetes and controls. The parameters 
estimating the separate effect of calendar time for type 2 diabetes and controls were transformed by raising this 
coefficient to the fifth power to represent the ratio between type 2 diabetes and controls over a 10-year period. 
A ratio of those hazard ratios shows the relative difference between the groups.
Post-cancer mortality for type 2 diabetes versus controls was estimated with a Cox regression model. In this 
model we adjusted for sex and the last pre cancer observation on age, education, marital status, and income since 
among the persons diagnosed for cancer during the study we no longer have balance with respect to age and 
gender between T2DM and controls. This estimation describes all-cause mortality following a cancer diagnosis. 
Critically, we also examined cancer specific mortality given that all-cause mortality might capture higher deaths 
rates from type 2 diabetes in general.
In all comparisons between type 2 diabetes and controls an estimated hazard ratio above 1.0 was interpreted 
as a greater event-rate among persons with type 2 diabetes than among controls.
To evaluate our current ability to predict cancer occurrences we evaluated the relative importance of all risk 
factors available in our database using Heller’s relative importance  model30. Heller’s  R2 generalises the normal  R2 
to a time-to-event setting. When estimating the influence of the risk factors we only included cancer-outcomes 
that were reported more than three years after the index date in an effort to mitigate reverse causality. In order 
to capture non linear associations between continuous risk factors and the outcomes studied, we modelled con-
tinuous variables using smoothing splines with five degrees of freedom. Smoothing splines essentially puts one 
knot at each observation and use penalization based on the total curvature in each knot (i.e. sum of the second 
derivatives) to allow the function to bend where it has to. The tuning parameter, the degrees of freedom, was 
set to five based on visual inspection of the spline curves and seems to capture most of the relevant variability 
without excessive wiggling. In an effort to both maximize the sample size and to avoid the assumption of miss-
ing completely at random we imputed missing data for the relative importance model using a single imputation 
using chained equations (MICE). Single imputation was chosen over multiple imputation due to the massive 
computational time.
A p value of < 0.05 was considered to indicate statistical significance, without any adjustment for multiple 
comparisons, implying that interpretations need to be cautious and based on patterns rather than single hypoth-
esis tests. All statistical analysis was conducted with SAS (version 9.4) and Rstudio (version 3.4.3).
Results
Baseline characteristics. Table 1 shows baseline characteristics in the overall cohort as well as broken 
down by diabetes diagnosed with less than 1 year of follow-up. Baseline characteristics were defined at the type 
2 diabetes person’s first observation in the NDR, which was also the index date for the matched controls. For the 
entire cohort, the mean age in both groups was 65.2 years. Median follow-up was 6.6 years. As could be expected, 
histories of cardiovascular diseases (CVD), and related outcomes were more frequent among persons with type 
2 diabetes. The mean age of those diagnosed with less than 1 year of follow-up was around 63.2 years and fewer 
diabetes patients had prior CVD or related complications but patterns of difference were broadly similar. The 
mean duration was 0.4 months in this case. As seen in Supplementary Table 2, the proportion of missing data 
ranged from practically zero for age and sex to very high (53.8%) for physical activity. Key variables such as 
HbA1c and BMI had 10.7% and 24.7% missing, respectively.
Causes of death. Figure 1 presents causes of death in patients with type 2 diabetes and controls from year 
1998 to 2012. Patients with type 2 diabetes primarily died from cardiovascular and endocrine causes in the initial 
years. However, rates of cardiovascular and endocrine death abated each year, such that CVD and endocrine 
causes represented 62.3% of deaths in the first year, and 44.4% of deaths in the final year. By contrast, cancer 
mortality increased gradually. In relative numbers, female cancer death rates increased by 103% with type 2 
diabetes and 40% for the matched controls. Death from cancer increased by 62% for males with type 2 diabetes 
while increasing only by 24% for matched controls. Remaining causes of death did not display any material trend 
over time. The logistical regression model suggested, if current trends continue, that by the year 2030 cancer 
would become the most common cause of death among individuals with type 2 diabetes and by 2040 in controls.
Cancer incidence and mortality. Risks in diabetes for the most common sites of cancer. Figure 2a displays 
results for the most common cancer sites in our cohort, which are in line with worldwide incidence rates of can-
cer. Results for all specific cancer sites can be found in the online-only supplementary material (Supplementary 
Figure 1).
Figure 2a panel A shows hazard ratios of incidence for all cancer and the four most common cancer sites. 
For all cancer, type 2 diabetes had a higher risk, with a HR of 1.10 (95% CI 1.09–1.12). For the most common 
cancer sites, risks HR were above one at 1.05 (95% CI 1.01–1.09) for breast cancer and 1.20 (95% CI 1.16–1.23) 
for colorectal cancer. They were lower for prostate cancer, and no different for lung cancer.
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Table 1.  Baseline characteristics for type 2 diabetes and controls using the entire cohort and restricting to 
those with less than one year since diagnosis. CHD coronary heart disease, CVD cardiovascular disease, AMI 
acute myocardial infarction, AF atrial fibrillation, HF heart failure, BMI body mass index, BP blood pressure, 
eGFR estimated glomerular filtration rate, HbA1c glycated hemoglobin, HDL high density lipoprotein, 
LDL low density lipoprotein, n number of patients. Diagnostic codes for the conditions listed are from the 
International Classification of Diseases, 9th Revision and 10th Revision. Percentages for the glycated hemoglobin 
level were based on values from the National Glycohemoglobin Standardization Program. The body-mass 
index is the weight in kilograms divided by the square of the height in meters. The glomerular filtration rate 
(GFR) was estimated with the use of the Modification of Diet in Renal Disease equation. Concentrations 
of glycated hemoglobin were based on values from the International Federation of Clinical Chemistry and 
Laboratory Medicine.
Variable
Type 2 diabetes 
(n = 457,473) Controls (n = 2,287,365)




Age—mean years (SD) 65.2 (12.6) 65.2 (12.6) 63.2 (12.9) 63.2 (12.9)
Female—no (%) 208,019 (45.47%) 1,040,095 (45.47%) 95,224 (45.77%) 476,120 (45.77%)
Place of birth—no (%)
Sweden 375,703 (82.13%) 2,003,918 (87.61%) 168,095 (80.80%) 902,774 (86.78%)
Europe, outside Sweden 48,676 (10.64%) 207,022 (9.05%) 22,747 (10.93%) 95,997 (9.23%)
Rest of the world 33,094 (7.23%) 76,425 (3.34%) 17,207 (8.27%) 41,474 (3.99%)
Education—no (%)
College level education 179,368 (40.16%) 882,155 (39.27%) 87,120 (42.74%) 421,488 (41.15%)
Elementary school educa-
tion 196,206 (43.93%) 829,593 (36.93%) 81,095 (39.78%) 336,101 (32.81%)
Upper secondary school 
education 71,028 (15.90%) 534,677 (23.8%) 35,632 (17.5%) 266,797 (26.0%)
Coexisting conditions—no (%)
CHD 79,096 (17.29%) 200,912 (8.78%) 30,536 (14.68%) 79,440 (7.64%)
HF 30,686 (6.71%) 74,807 (3.27%) 11,514 (5.53%) 28,376 (2.73%)
Hyperglycemia 5976 (1.31%) 704 (0.03%) 1360 (0.65%) 175 (0.02%)
Amputation 1729 (0.38%) 2368 (0.10%) 472 (0.23%) 958 (0.09%)
Psychiatric disorders 13,651 (2.98%) 44,934 (1.96%) 7288 (3.50%) 21,816 (2.10%)
Renal disorders 1021 (0.22%) 3004 (0.13%) 350 (0.17%) 1268 (0.12%)
Cancer 33,799 (7.39%) 161,217 (7.05%) 14,560 (7.00%) 69,292 (6.66%)
Gastric bypass 322 (0.07%) 602 (0.03%) 115 (0.06%) 343 (0.03%)
Diabetes duration—year 
(SD) 5.7 (7.1) 0.4 (0.5)
BMI (kg/m2)—mean (SD) 29.7 (5.4) 30.3 (5.6)
HbA1c(mmol/mol): 
median (Iq) 54.5 (14.9) 52.8 (15.7)
SBP(mmHg)—mean (SD) 140.2 (18.3) 138.2 (17.8)
DBP(mmHg)—mean (SD) 78.7 (9.9) 79.4 (10.0)
Total Chol (mmol/L)—
mean (SD) 5.1 (1.1) 5.2 (1.1)
LDL(mmol/L)—mean 
(SD) 2.9 (1.0) 3.1 (1.0)
HDL(mmol/L)—mean 
(SD) 1.3 (0.4) 1.2 (0.4)
Trig(mmol/L)—median 
(iq) 1.9 (1.2) 2.0 (1.3)
eGFR—median (Iq) 80.5 (25.3) 83.2 (25.1)
Diabetes treatment—no (%)
Diet only 172,642 (37.7%) 108,655 (52.2%)
Tablets 195,194 (42.6%) 82,496 (39.6%)
Insulin 47,635 (10.41%) 10,312 (4.96%)
Tablets and insulin 42,246 (9.23%) 6586 (3.17%)
Anti-hypertensive treat-
ment 276,011 (64.3%) 119,017 (61.6%)
Lipid lowering treatment 170,342 (39.8%) 72,491 (37.5%)
Micro Albuminurea 22,009 (6.89%) 6215 (4.81%)
Macro Albuminurea 39,570 (15.43%) 13,502 (12.87%)
Smoking 57,458 (15.62%) 27,424 (17.46%)
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Table 2 displays a comparison of cancer rates when we compared the entire cohort to risks in those with 
less than 1 year of follow-up relative to matched controls in each case. Of importance, the patterns of cancer 
risk were broadly same, though notably, overall cancer risks were higher at 1.22 (1.17–1.27) and risks for most 
individual cancers were somewhat higher, notably for pancreatic cancer with HR of 2.72. However, in nearly all 
cases, HRs overlapped.
Figure 2a panel C displays hazard ratios of post-cancer mortality for the most common cancer sites in type 2 
diabetes as compared to controls. For overall cancer mortality we observed a HR of 1.23 (95% CI 1.21–1.25) for 
patients with type 2 diabetes, compared with controls. They were also higher for breast, colorectal and prostate 
cancer but not for lung cancer.
Figure 2a panel D displays hazard ratios of post-cancer cancer-specific mortality. Overall, we observed a HR 
of 1.14 (95% CI 1.11, 1.16) for patients with type 2 diabetes, compared with controls, with higher cancer-specific 
mortality seen in prostate, HR 1.09 (95% CI 1.03–1.16), but not for breast or colorectal cancer.
The sites most associated with higher risk of cancer in patients with type 2 diabetes. Figure 2b panel A shows 
hazard ratios of incidence for the most associated cancer sites for type 2 diabetes as compared to controls, which 
were: liver, pancreas, uterus, penis, kidney, gallbladder and bile ducts, stomach and bladder, along with colorec-
tal cancer. We observed the highest hazard ratios for liver cancer HR 3.31 (95% CI 3.07–3.58); pancreas cancer 
HR 2.19 (95% CI 2.06–2.32); and corpus uterus cancer HR 1.78 (95% CI 1.68–1.88). Overall, the excess risk of 
these cancers ranged from 1.2- to 3.3-fold.
Figure 2b panel C shows hazard ratios for post-cancer mortality for sites most associated with type 2 diabe-
tes as compared to controls. Overall mortality risks were higher in type 2 diabetes only for uterine and bladder 
cancer.
Figure 2b panel D displays hazard ratios of post-cancer and cancer-specific mortality for the most common 
cancer sites. There was no real evidence of meaningful excess cancer-specific mortality for any of the cancers 
which are most associated with type 2 diabetes.
Trends in cancer incidence. Figure 3 along with panels B of Fig. 2 displays time trends in cancer incidence. 
Of the four most common cancer sites a significant difference in change of risk over time was only observed for 
lung cancer, with a 30% greater increase in incidence over a 10-year period for type 2 diabetes compared to 
controls. For the sites that were most associated with type 2 diabetes, only pancreatic cancer and uterine cancer 
showed a significant difference in change of risk over time in type 2 diabetes as compared to controls, with a 38% 
greater increase in incidence over a 10-year period for pancreas cancer, but a 26% greater decrease for uterine 
cancer for type 2 diabetes compared to controls.
Risk factor analysis. Supplementary Figure 2 shows relative importance of traditional risk factors collected 
in routine diabetes practice. All 15 risk factors collectively contributed very little to overall cancer prediction.
When we looked at relative importance separately by sex and in non-smokers only (Supplementary Fig-
ures 3 and 4) we noticed BMI to be the most important risk factor for cancer in women  (R2 = 0.0042) but not 
in men  (R2 = 0.00012) in whom eGFR  (R2 = 0.0010) and physical activity  (R2 = 0.00049) showed greatest relative 
Figure 1.  Causes of death in Sweden between 1998 and 2012. (a) Results for males with type 2 diabetes and 
controls, (b) results for females with type 2 diabetes and control.
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importance, although, once again, overall risk factors contributed little to cancer prediction. Notably, when we 
added diabetes duration, this did not make a meaningful difference to associations (Supplementary Figure 5–7).
Finally, to further address detection bias and reverse causation, we added yearly incidence rates following type 
2 diabetes diagnosis (split by sex) where we found that only pancreas cancer had a higher incidence rate during 
the first years following diagnosis of type 2 diabetes (Supplementary Figure 8). For interest, we also present the 
data for all cancers (Supplementary Figure 9). We have also performed landmark analyses comparing type 2 
diabetes to controls, where we exclude the first one, two and three years of follow up (Supplementary Table 3). 
These data show nearly all associations remain robust with little variance, perhaps excluding pancreas cancer 
where we see a lowering of overall HR for all cancers from 1.10 (1.09, 1.12) to HR 1.07 (1.05, 1.08), the latter being 
the 3 year landmark analyses. That noted, some associations became stronger (specifically liver) whereas others 
become modestly weaker (e.g. Pancreas and stomach), though most HRs seemed to remain broadly consistent.
Figure 2.  Hazard ratios for cancer incidence, 10-year trends, post-cancer mortality, and cancer specific 
survival in Type 2 diabetes patients versus matched controls. (Red) Hazard ratios of incidence; (Green) hazard 
ratios for 10-year trends in incidence; (Blue) hazard ratios for post-cancer mortality for the most common (a) 
and most associated (b) cancer sites. Incidence model adjusted for sex, education, income, marital status and 
geographical region of birth. Time trends in incidence were adjusted for age and gender. Post-cancer mortality 
model adjusted for sex, age, education, marital status and income.
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Discussion
Even though general cancer trends in Sweden seem to match those in other high income  countries31, this is one 
of the largest studies to present several dimensions in cancer-associated risks in type 2 diabetes. We demon-
strate a 10% higher risk of cancer in general in those with type 2 diabetes (22% higher if we restricted analyses 
to diabetes patients with less than 1 year of duration), with risks even higher in several cancers linked to obesity 
(uterine, colorectal and breast). We furthermore present a 14% overall higher cancer-specific mortality and a 
rapid shift towards greater relative cancer mortality: women with type 2 diabetes experienced a 103% increase in 
cancer death rates, whereas men experienced a 62% increase. Corresponding figures for people without type 2 
diabetes were 40% and 24%, respectively. Consequently, if current trends continue, by the year 2030 cancer may 
become the most common cause of death in type 2 diabetes and by 2035 in controls; yet, our ability to predict 
cancer is at best poor. This suggests it may take longer for cancer mortality to equal CVD mortality in patients 
with diabetes since PURE data recently showed cancer deaths to have already overtaken CVD deaths in general 
in middle age people in high income  countries32.
Moreover, by comparing our incident risks with prior excellent research linking BMI to  cancers23 we clearly 
show that type 2 diabetes has an effect on the risk for many cancers (in particular liver and pancreas) that goes 
well beyond any effect of total adiposity per se. Our results in Sweden for overall cancer incidence risks, and 
observed magnitudes and patterns of risk by cancer type, are very much in line with those reported by Harding 
et al33 in 2015 who examined standardised incidence ratios in over 800 K people with type 2 diabetes in Australia, 
albeit over a shorter 11 years time period. Our findings therefore have strong external validity. Furthermore, 
whilst both Harding et al. and our study in Sweden showed pancreatic cancer to have the strongest evidence of 
detection bias, in both cases the level of excess risk remained high after the first few months or years. Whilst 
we could not see any great evidence of detection bias for other types of cancer, Harding et al., whose study had 
more power, did note some minor evidence for such bias for some cancers. However, once again, such potential 
biases were modest and insufficient to explain excess risks for many cancers. The two studies together therefore 
provide strong evidence for excess cancer risks in type 2 diabetes that cannot be explained by detection bias.
The individual cancer data were broadly comparable to findings in the entire cohort when we used patients 
with less than one years duration although, due to smaller numbers, the confidence intervals were inevitably 
wider (Table 2). Notably, however, the point estimate of risk for total cancers was not lower in this group but, if 
anything, it was slightly higher (1.22 vs 1.10). That said, both approaches have different potential biases but the 
fact that each gave similar patterns in risks is reassuring.
We believe our data show that obesity cannot explain all the excess risks of cancers in type 2 diabetes. 
The excess risks were markedly pronounced for liver (221% higher risk or 136% higher for newly diagnosed 
diabetes) and pancreatic (119% higher risk or 176% higher for newly diagnosed diabetes) cancers. These risk 
levels are far greater (by around five–tenfold) than Bhaskaran et al.  previously23 suggests could be accounted 
for by obesity which showed that a five unit higher BMI (a typical type 2 diabetes to non-type 2 diabetes cohort 
BMI difference), was associated with an increased liver cancer risk by only 26% and pancreatic by 11% in non-
smokers (Supplementary Table 4). Our work therefore extends Pearson-Stuttard et al.’s8 observations suggesting 
independent effects of obesity and diabetes on cancers, with greater type 2 diabetes effects on cancers like liver 
and pancreas. Thus, pathways leading to glucose dysregulation must add considerable neoplastic potential for 
these two sites. In addition, risks for several non-obesity related cancers (bladder by 20%, penile by 56%, and 
lip by 27%) were also higher in type 2 diabetes, whereas risks for other cancers (e.g. stomach [20%], colorectal 
Table 2.  Hazard ratios for cancer incidence using the entire cohort and then restricting diabetes patients to 
those with < 1 year since diagnosis (mean duration 4 months). HRs are relative to age, sex and county-matched 
controls in each case, as per data in Table 1. Model adjusted for sex, education, income and marital status.
All diabetes Newly diagnosed (< 1 year)
Most common cancers
All cancer 1.10 (1.09–1.12) All cancer 1.22 (1.17–1.27)
Breast 1.05 (1.01–1.09) Breast 1.12 (1.02–1.23)
Lung 1.01 (0.97–1.05) Lung 1.18 (1.04–1.34)
Prostate 0.82 (0.80–0.83) Prostate 0.80 (0.70–0.90)
Colorectal 1.20 (1.16–1.23) Colorectal 1.30 (1.18–1.43)
Most associated cancers
Liver 3.31 (3.07–3.58) Liver 2.36 (1.74–3.20)
Pancreas 2.19 (2.06–2.32) Pancreas 2.72 (2.28–3.25)
Corpus uteri 1.78 (1.68–1.88) Corpus uteri 1.68 (1.44–1.96)
Gallbladder 1.32 (1.13–1.54) Gallbladder 1.55 (1.02–2.37)
Kidney 1.45 (1.36–1.54) Kidney 1.78 (1.45–2.19)
Penis 1.56 (1.27–1.91) Penis 1.96 (0.77–4.99)
Stomach 1.21 (1.13–1.30) Stomach 1.37 (1.06–1.77)
Bladder 1.20 (1.15–1.25) Bladder 1.15 (0.96–1.37)
Colorectal 1.20 (1.16–1.23) Colorectal 1.30 (1.18–1.43)
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[20%], kidney [45%]) also seem greater than a 5-unit higher BMI would  predict23. These observations collectively 
suggest that type 2 diabetes-associated excess cancer risks, whilst contributed to by obesity, simply cannot be 
explained by this risk factor alone and that some other aspects of diabetes pathogenesis or hyperglycaemia must 
Figure 3.  Time trends in cancer incidence. The most common and most associated sites. The x-axes show 
calendar years from 1998 to 2013. The y-axes display standardised incidence rates (note the differing limits on 
the y-axes). Blue lines represent people with type 2 diabetes and red lines represent matched controls from the 
general population. Model was adjusted for sex, education, income and marital status.
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be involved. The fact that cancer risks are also increased in type 1 diabetes, adds further support for a potential 
role of  hyperglycaemia34.
Perhaps most importantly, after a diagnosis of cancer, patients with type 2 diabetes had a 14% higher risk 
of death due to cancer. These findings suggest any bias in cancer detection in type 2 diabetes is at best mod-
est, and that once cancer develops, greater overall mortality is evident compared to non-diabetes people with 
cancer. Notably, whilst post cancer mortality was no different for many aggressive cancers (e.g. liver, pancreas, 
stomach etc.), it was 9% (95% CI 3–16%) higher after a diagnosis of prostate cancer, suggesting either later 
detection in type 2 diabetes, perhaps due to obesity-related effects on PSA levels, or that such cancers may be 
more  aggressive35.
Cancer incidence and time trends in incidence. With the most common cancer sites accounting for 
four out of ten cancer occurrences  worldwide36, even the small increase or decrease in incidence for type 2 
diabetes noted in our study might have a major impact. Patients with type 2 diabetes displayed a 30% (95% CI 
1.12–1.52) greater increase in lung cancer incidence over the study period which is interesting and perhaps 
unexpected. These results might be explained by competing risk. With mortality from cardiovascular disease 
decreasing for type 2 diabetes compared to  controls37,38, patients with type 2 diabetes are surviving their cardio-
vascular diseases, and hence living longer, and as a consequence lung cancer incidence increases in this group. 
Smoking is of course a major risk factor of lung cancer and is associated with both type 2 diabetes and  CVD10. 
Interestingly when analysis was made separately for males and females for lung cancer, we found that for females 
there was an increasing incidence rate for both T2DM and controls, while for men the incidence rate was con-
stant for persons with T2DM and decreasing for the controls. That noted, when we did a formal competing risk 
analysis (by fitting a Fine & Grey model including lung cancer and death from any cause as the two competing 
events), the estimated subdistribution hazard ratio for lung cancer comparing persons with T2DM to controls 
turned out to be 1.03 with 95% CI (0.99, 1.06) which failed to reach statistical significance with p = 0.1731. For 
uterine cancer, there was a 78% higher risk for T2DM compared to controls but a 26% greater decrease in this 
excess risk over a 10-year period in type 2 diabetes. Long-term incidence trends also revealed that type 2 diabetes 
had a 38% greater increase in risk of pancreatic cancer over time. The reasons for these changes are not clear, 
and more work is needed to better understand and validate pancreatic risk changes over time in type 2 diabetes. 
If such risks are increasing, as we seem to show, this is a worrying trend given mortality rates from pancreatic 
cancer remain very high.
Post‑cancer mortality. The paradoxical finding, that the incidence of prostate cancer is lower, but mortal-
ity in total is higher in type 2 diabetes as compared to controls, has been described  previously5,10,39–42. Cancer 
specific mortality was higher by 14% for all cancers when combined and, interestingly, significantly elevated only 
in prostate cancer, a novel finding. The sites that did not show a significant difference between groups for post-
cancer mortality (or indeed cancer-specific mortality) were lung, gallbladder and bile ducts, kidney, stomach, 
liver, and pancreas. For all but penis cancer these results stem from the fact that these are generally aggressive 
cancers and they have a low average 5 year  survival43.
Strengths and limitations. We acknowledge we only had risk factor data, including BMI and smoking, in 
type 2 diabetes patients and whilst the patterns of excess cancer risks somewhat match those previously linked 
to obesity per se, it is clear that risks for some cancers are far in excess of any possible links to obesity whereas 
for others risks are higher than that explainable by obesity alone. In addition, risks are also increased for other 
cancers not previously linked to obesity. Of the cancer sites we found to be associated with T2DM, studies have 
shown that smoking is strongly associated with lung, stomach, kidney, bladder, pancreas, upper digestive tract 
and liver  cancer10. It is also thought to be an independent risk factor for T2DM development, and it is therefore 
likely that T2DM cohorts smoked more than the  controls10. In our cohort there were 15% who were reported 
as smokers and it is estimated that 9% of the Swedish general population  smokes44. The relative importance 
model found smoking to be the second most important risk factor for the development of all cancer, but still 
only explaining very little of the variation in all cancer risk. It is therefore possible that our estimations of asso-
ciation between T2DM and cancer are somewhat confounded by smoking. We also did not have BMI in our 
control population and could therefore not examine the impact of undiagnosed cancer, as possibly evidenced 
by cachexia, on the risk of cancer in people with diabetes. Finally, we recognise the potential for detection bias 
and reverse causation could be relevant to our findings and to this end, we provide data to show the risks for key 
cancers we discuss remain intact even after removing the first three years of follow-up. We also show only pan-
creatic cancer seemed to be picked up more in the year after diagnosis, whereas little evidence for other cancers.
We did not include analysis on diabetes treatment in our study but do not consider that to be a limitation. 
The role of diabetes medication in cancer risk has been immensely  studied10,45–51. There are numerous studies 
that show a decrease in cancer incidence for patients on  metformin4,10,11,47,51–53. However, most of these findings 
have been found to be due to systematic bias such as immortal time bias, time-lag bias and time-window bias. 
This is partly due to misclassification of study participants, resulting in a reduction of risk. Many newer obser-
vational studies that minimized the effect of systematic bias did not find an association between metformin use 
and cancer risk  reduction47,52–54. Metformin is the drug of choice for T2DM and results have been confounded 
by the fact that the drug is usually prescribed to people with a short duration of diabetes and those who do not 
have contraindicating factors that might be factors involved in risk of  cancer10,54,55.
The ability to track both incidence and post-cancer total and cause-specific mortality helps mitigate concerns 
about potential biases from detection bias and reverse causation, although we accept some such biases remain 
possible. We realise that the prevalent cases may have suffered from a depletion of ‘susceptibles’. However, when 
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we looked at the incident subcohort and plotted cumulative incidence as a function of time from diagnosis we 
found no evidence of any short-term increase in incidence rate during the first years, except for pancreatic cancer. 
We also examined risks in those with diabetes diagnosed under a year and found our results to be broadly similar 
to those in the fuller cohort. Even so, for sake of clarity, we have presented findings from both approaches so that 
readers can compare and contrast results. Finally, this work reflects predominately risks in white individuals in 
a high-income country and thus it cannot be used as a proxy for such work in low and middle-income countries 
where patterns of disease risks will be different due to rising cardiovascular risks.
Conclusion
Persons with type 2 diabetes are at greater risk of developing cancer and a lower chance of surviving it, although 
such risks vary by cancer types. Whilst obesity might explain excess risks for many cancers, risks for specific 
cancers go well beyond obesity. As proportionately more people with type 2 diabetes are dying from cancer over 
time, cancer may become its most common cause of death within a decade if current trends continue, a pattern 
lagging behind such trends in the general population. Even so, more work on how to better prevent cancers in 
type 2 diabetes is urgently needed.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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